Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Is pericarditis dangerous?
Risks, prognosis and complications

In most patients with idiopathic or presumed viral pericarditis, the prognosis is good and the episode resolves with appropriate treatment. This does not mean, however, that all forms of pericarditis are equivalent. Risk varies according to the cause, the amount of fluid that may be present around the heart, myocardial involvement, and certain features that can already be observed at presentation.
The most frequent complication is not an immediately life-threatening consequence, but recurrence: after a first episode, pericarditis can return. More rarely, a large effusion with cardiac tamponade or constrictive pericarditis may occur. Some specific forms, especially bacterial, purulent, tuberculous or neoplastic pericarditis, require a more intensive assessment because their risk profile differs from that of idiopathic forms.

The main features that make pericarditis more concerning are:


Pericarditis actually includes very different clinical pictures. This guide answers the practical question "how dangerous is it?", while the specialist monograph examines causes, classification, pathophysiology and treatment in depth.

When pericarditis generally has a favorable prognosis

Acute idiopathic or presumed viral forms without high-risk features generally have a favorable course. With appropriate treatment, clinical remission often occurs within a few weeks; European guidelines describe for acute pericarditis without complications a typical course toward remission within about 4-6 weeks.
Actual duration varies from person to person. Rapid disappearance of pain does not always mean complete resolution of inflammation, which is why treatment duration and return to physical activity should not be decided solely on the basis of perceived symptoms.

The most common complication is recurrent pericarditis. The 2025 ESC guidelines indicate recurrence in about 15-30% of patients after a first episode; the risk may increase after a first recurrence, especially when the initial episode was treated inadequately, therapy was tapered too quickly, colchicine was not used when indicated, or corticosteroids were used inappropriately.
This helps put the idea of "danger" into perspective: many people recover without consequences, whereas for a meaningful proportion the main problem is the tendency of inflammation to flare again and prolong the course of treatment.

Which signs make pericarditis higher risk

The guidelines identify certain red flags associated with a greater likelihood of a specific cause or complications. The main ones are fever above 38 °C, subacute onset, a large pericardial effusion, cardiac tamponade, and lack of response to aspirin or NSAID therapy after at least one week. These are not merely theoretical criteria: they are used to decide how extensively to investigate the cause and whether the patient should be managed in hospital.
Other features are also considered relevant, including myocardial involvement, immunosuppression, recent trauma and anticoagulant therapy. Their presence requires consideration of the overall clinical context and does not allow the case to be automatically classified as "benign".

A patient without these features can often be managed as an outpatient after appropriate assessment, whereas the presence of one or more red flags generally leads to a more complete evaluation. The essential point is that the prognosis of pericarditis does not depend only on pain: very severe pain may occur in a form that responds well to treatment, whereas a significant effusion or a specific cause may require greater attention even if the pain is not dramatic.

What complications can occur

The first complication to know about is recurrence. Recurrent pericarditis is diagnosed when, after a documented episode and a period of remission, signs and symptoms of pericardial inflammation appear again. A recurrence can be very troublesome and may require months of treatment, but it does not in itself imply an unfavorable cardiac prognosis. The main issue is controlling inflammation and preventing further episodes.
A second complication is pericardial effusion. A small amount of fluid may accompany pericarditis without hemodynamic consequences; what matters is the amount, how quickly the fluid accumulates, and its effect on filling of the heart chambers.

Cardiac tamponade occurs when pressure from the fluid prevents the heart from filling normally and reduces cardiac output. It is an urgent condition that may require drainage of the fluid. Risk does not depend only on the millimeters of effusion: rapid accumulation may cause tamponade with relatively small volumes, whereas very slow accumulation may be tolerated for longer.
Constrictive pericarditis is instead a complication in which the pericardium loses its normal elasticity and limits cardiac filling. In idiopathic or presumed viral forms it is rare, with a risk below 1% according to ESC guidelines; it becomes more likely in some specific etiologies.

Why the cause of pericarditis changes the risk

Not all forms of pericarditis have the same natural history. Idiopathic and presumed viral forms are the ones most likely to have a favorable course. Forms associated with autoimmune diseases or neoplastic processes may have a different course and require treatment of the underlying condition above all.
Bacterial pericarditis, particularly purulent and tuberculous forms, carries a significantly higher risk of complications and progression to constriction. The 2025 ESC guidelines indicate a risk of constrictive pericarditis below 1% in viral or idiopathic forms, intermediate in immune-mediated and neoplastic forms, and much higher in bacterial forms.

Myocardial involvement also changes the picture. When inflammation affects not only the pericardium but also the myocardium, ventricular function, troponin level, possible arrhythmias and cardiac magnetic resonance findings become important. In these cases, physical activity restrictions and follow-up may be stricter than for isolated pericarditis.
For this reason, the question "is pericarditis dangerous?" does not have the same answer for everyone: the same term includes conditions with very different levels of risk.

How to reduce the risk of recurrences and complications

The first step is to follow treatment at the dose, duration and tapering schedule established by the physician. In an acute episode, anti-inflammatory therapy is generally combined with colchicine, which reduces the risk of recurrences. Stopping too early or tapering medication too quickly can promote persistent inflammation and return of symptoms.
Corticosteroids are not a shortcut to use independently. They have specific indications and, if used inappropriately or tapered too quickly, can make recurrent disease harder to control. Targeted therapies are now available for more difficult recurrent cases, including drugs directed against interleukin-1, but they belong to selected specialist treatment pathways.

During the active phase it is important to respect restrictions on physical activity and return gradually after clinical remission according to the instructions received. It is also useful to attend scheduled follow-up visits and report recurrent pain, fever, increasing shortness of breath or a marked reduction in exercise tolerance.
In the presence of fainting, severe breathing difficulty, hypotension, significant chest pain or rapid deterioration, the situation should not be treated as an ordinary "flare": urgent assessment is required.

Frequently asked questions about the risks of pericarditis

Can you die from pericarditis?
Idiopathic or presumed viral forms generally have a favorable prognosis. Some specific forms and complications such as tamponade can, however, be serious and require urgent treatment.

What is the most frequent complication?
Recurrence is the most common complication after a first episode.

When is pericarditis considered higher risk?
Main high-risk features include fever above 38 °C, subacute onset, a large effusion, tamponade and lack of response to aspirin or NSAIDs after at least one week.

Can pericarditis become chronic?
Yes. Incessant, recurrent and chronic forms exist. Permanent constriction is nevertheless rare in idiopathic or viral forms.

How can the risk of recurrence be reduced?
By following treatment correctly, avoiding independent changes and respecting recommendations on physical activity. Colchicine, when indicated, reduces the risk of new episodes.

Bibliography
  1. Schulz-Menger J, Collini V, Gröschel J, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041. doi:10.1093/eurheartj/ehaf192.
  2. Wang TKM, Klein AL, Cremer PC, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis. Journal of the American College of Cardiology. 2025;86(25):2691-2719. doi:10.1016/j.jacc.2025.05.023.
  3. Klein AL, Wang TKM, Cremer PC, et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988. doi:10.1016/j.jcmg.2024.04.010.
  4. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal. 2015;36(42):2921-2964. doi:10.1093/eurheartj/ehv318.
  5. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020;75(1):76-92. doi:10.1016/j.jacc.2019.11.021.
  6. Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739-2744. doi:10.1161/CIRCULATIONAHA.106.662114.
  7. Imazio M, Brucato A, Cemin R, et al. A Randomized Trial of Colchicine for Acute Pericarditis. New England Journal of Medicine. 2013;369(16):1522-1528. doi:10.1056/NEJMoa1208536.
  8. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Annals of Internal Medicine. 2011;155(7):409-414. doi:10.7326/0003-4819-155-7-201110040-00359.
  9. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2). The Lancet. 2014;383(9936):2232-2237. doi:10.1016/S0140-6736(13)62709-9.
  10. Spodick DH. Acute Pericarditis: Current Concepts and Practice. JAMA. 2003;289(9):1150-1153. doi:10.1001/jama.289.9.1150.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.